IP Library Granted Patent US 8,709,491
Granted Patent B2
US 8,709,491 · App. 13/947,881 · Granted Apr 29, 2014

Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles

Inventors: Mark Tengler (Colleyville, TX); Russell McMahen (Flower Mound, TX)
Assignee: NEOS Terapeutics, LP
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,491
App. No.
13/947,881
Granted
Apr 29, 2014
Kind
B2
Abstract

The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. In a particular embodiment, the drug dosage form comprises a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.

Claims (9)

1. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises 20 to 50% of a first plurality of drug-resin particles that are uncoated and 50 to 80% of a second plurality of drug-resin particles that are coated with a delayed release coating.

2. The composition of claim 1 , wherein the second plurality of drug resin particles comprises a triggered-release coating triggered by a pH change.

3. The composition of claim 2 , wherein the triggered-release coating is cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/acrylic acid ethyl esters, or mixtures thereof.

4. The composition of claim 1 , wherein the resin particles are strong acidic cation exchange resins, selected from the group consisting of polistirex, polacrilex, cholestyramine, polacrilin or mixtures thereof.

5. The composition of claim 1 , wherein the composition comprises 40%-50% of the first plurality of drug-resin particles and 50-60% of the second plurality of drug-resin particles.

6. The composition of claim 5 , wherein the composition comprises about 45% of the first plurality of drug-resin particles and about 55% of the second plurality of drug-resin particles.

7. The composition of claim 1 , wherein the composition is a liquid suspension, chewable composition, or an orally disintegrating tablet composition.

8. The composition of claim 1 , wherein said drug-resin particles comprise 25% levo-amphetamine and 75% dextro-amphetamine.

9. The composition of claim 1 , wherein the amount of ADHD effective agent is 2-60 mg.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 067728/0327 →
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2024
From: DEERFIELD MGMT, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 066725/0043 →
SECURITY INTEREST Recorded Feb 10, 2022
From: NEOS THERAPEUTICS, LP
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 058977/0069 →
RELEASE OF SECURITY INTEREST Recorded Jan 28, 2022
From: DEERFIELD MGMT, L.P.
To: NEOS THERAPEUTICS, LP
Reel/Frame 058814/0437 →
SECURITY INTEREST Recorded Oct 7, 2019
From: NEOS THERAPEUTICS, LP
To: DEERFIELD MGMT, L.P., AS COLLATERAL AGENT
Reel/Frame 050638/0952 →
SECURITY INTEREST Recorded Oct 2, 2019
From: NEOS THERAPEUTICS, LP
To: ENCINA BUSINESS CREDIT, LLC, AS AGENT
Reel/Frame 050606/0096 →
SECURITY INTEREST Recorded Jun 15, 2016
From: NEOS THERAPEUTICS, LP
To: DEERFIELD MGMT, L.P., AS COLLATERAL AGENT
Reel/Frame 038918/0965 →
CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF INVENTOR RUSSELL MCMAHEN PREVIOUSLY RECORDED ON REEL 032237 FRAME 0119. ASSIGNOR(S) HEREBY CONFIRMS THE ADDITION OF RUSSELL MCMAHEN AS THE SECOND INVENTOR. Recorded Feb 20, 2014
From: TENGLER, MARK; MCMAHEN, RUSSELL
To: NEOS THERAPEUTICS, LP
Reel/Frame 032301/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2014
From: TENGLER, MARK
To: NEOS THERAPEUTICS, LP
Reel/Frame 032237/0119 →
Continuity (5)
Continuation 13844537 · Mar 15, 2013
Continuation In Part PCTUS2012044698 · Jun 28, 2012
Provisional Application 61502189 · Jun 28, 2011
Provisional Application 61528554 · Aug 29, 2011
Related Publication 20140050796A1 · Feb 20, 2014